Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028496 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study of Male Breast Cancer and Adenocarcinoma of the Rectum, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00028496: Completed Phase 1 study of Male Breast Cancer and Adenocarcinoma of the Rectum, sponsored by National Cancer Institute (NCI).
NCT00028496 is a Phase 1 study of Male Breast Cancer and Adenocarcinoma of the Rectum that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants, above the 33-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028496, a Phase 1 study of Male Breast Cancer and Adenocarcinoma of the Rectum, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells
Conditions Studied
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant fowlpox GM-CSF vaccine adjuvant
- BIOLOGICAL recombinant fowlpox-CEA(6D)/TRICOM vaccine
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2001-11 |
| Phase | Phase 1 |
What the finished NCT00028496 record still lists
NCT00028496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, above the 33-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (45% higher).
The record links to 10 conditions, with Male Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which sargramostim is the first listed.
NCT00028496 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00028496 about?
NCT00028496 is a clinical study titled "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer". Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of im...
What is the current status of trial NCT00028496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2001-11.
What conditions does trial NCT00028496 study?
This clinical trial studies the following conditions: Male Breast Cancer, Adenocarcinoma of the Rectum, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Advanced Adult Primary Liver Cancer.
What interventions are being tested in trial NCT00028496?
The interventions under investigation include: sargramostim (BIOLOGICAL), recombinant fowlpox GM-CSF vaccine adjuvant (BIOLOGICAL), recombinant fowlpox-CEA(6D)/TRICOM vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028496?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00028496 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00028496's enrollment target sits among peer trials
48 5th of 14 higher than 10 of 14 other Male Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Male Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
-
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
COMPLETED · Phase 1
-
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia